Matrix Metalloproteinase-13 Is an Unfavorable Prognostic Factor in Chordoma by Digesting Growth Inhibitory Collagens

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Chordomas are invasive tumors with limited treatment options.
• Some chordomas feature cartilage-like extracellular matrix (ECM).
• The role of collagenases in chordoma progression is not well understood.

Purpose of the Study:

• To investigate the expression and clinical significance of collagenases, specifically matrix metalloproteinase (MMP)13, in chordomas.
• To determine the relationship between MMP13 expression, ECM phenotype, and patient outcomes.
• To explore the functional role of MMP13 in chordoma cell behavior and extracellular matrix interaction.

Main Methods:

• Immunohistochemistry and immunofluorescence were used to analyze MMP13, MMP9, and cathepsin K expression in chordoma tissues.
• Safranin-O staining categorized ECM phenotype (cartilage-like vs. non-cartilage-like).
• Gene expression, protein localization, collagen digestion assays, and cell growth assays were performed using JHC7 chordoma cells and collagen types I (COL1) and II (COL2).

Main Results:

• Chordomas lacking safranin-O staining (non-cartilage-like ECM) showed significantly shorter progression-free survival (PFS).
• MMP13 expression was higher in safranin-O negative chordomas compared to safranin-O positive ones.
• JHC7 cells degraded COL2, an activity partially inhibited by an MMP13-specific inhibitor, and COL2 inhibited cell growth more effectively than COL1.

Conclusions:

• MMP13 may contribute to aggressive chordoma behavior by degrading growth-inhibitory COL2-rich ECM.
• MMP13 expression levels could serve as an unfavorable prognostic marker for chordoma patients.
• MMP13 represents a potential therapeutic target for chordoma treatment.